news
Effective analgesics are ‘some way away’ due to bias in pain research, says researcher
A review of pain research suggests it is biased towards males, despite most chronic pain sufferers being female, resulting in ineffective analgesics.
List view / Grid view
Drug Development
article
Drug Target Review – Issue 2 2020
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
article
Empty phage viruses as a method to combat influenza
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
news
White blood cells as a novel early indicator of vaccine efficacy
Researchers demonstrate that a subpopulation of circulating white blood cells can act as an early indicator of vaccine efficacy, with potential implications for COVID-19 drug development.
news
Researchers use algorithm to design articifical proteins for vaccines
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
news
Adding RPL6 protein to vaccine prevents malaria in mice, find researchers
Researchers have shown that adding the RPL6 protein to malaria vaccines was successful at protecting mice against the condition.
news
Oxford University and NIH COVID-19 vaccine shows success in rhesus macaques
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
news
Combination of two neutralising antibodies suggested as COVID-19 treatment
Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
news
Researchers develop promising MERS vaccine, with potential for COVID-19
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
article
Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
article
Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
article
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
news
NIAID releases strategic plan, outlining COVID-19 research priorities
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
news
Novel antibody slows cancer growth and metastasis in mice
The antibody targets a cell receptor in blood vessels and slowed breast and lung cancer growth as well as metastasis in murine models.
news
Hyperferritinaemia could be causing severe COVID-19
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
